HKG:6955

3 stories mentioning HKG:6955Updated 8d ago

Every FINWIRES story that references HKG:6955, newest first.

Boan Biotechnology Licenses Diabetes Drug Biosimilar in US

Shandong Boan Biotechnology (HKG:6955) licensed BA5101 to a partner in the U.S., according to a Thursday filing with the Hong Kong bourse.The firm's partner will be responsible for commercializing the diabetes treatment in the U.S., including the submission of the biologics license application and sales.BA5101, also known as dulaglutide, is a biosimilar version of Trulicity.The company said it is eligible for an upfront payment, as well as milestone payouts and sales commissions.

HKG:6955

Asia37d ago

Boan Biotechnology Announces HK$200 Million Share Buyback

Shandong Boan Biotechnology (HKG:6955) announced plans to buy back up to HK$200 million of its shares, according to a Wednesday filing with the Hong Kong bourse.The pharmaceutical company's shares gained over 3% in morning trade Thursday.

HKG:6955

Asia54d ago

Boan Biotechnology's Phase 2 Cancer Drug Trial Application Accepted for Review in China

Shandong Boan Biotechnology (HKG:6955) said Chinese regulators had accepted the firm's application to conduct a phase 2 trial of BA1106 in lung cancer for review, according to a Hong Kong bourse filing Sunday.Shares of the pharmaceutical company gained over 2% in morning trade Monday.The company is seeking approval to study the drug in combination with another of its medicine, BA1104, as a first-line or second-line treatment of non-small cell lung cancer.

HKG:6955

Track with the FINWIRES app suite

FolioX

Track HKG:6955 in your portfolio

WheelAI

Analyze HKG:6955 options with the wheel strategy

StockInsider

See market sentiment on HKG:6955